Univercells Technologies introduces new upstream platform for virus manufacturing
The NevoLine Upstream platform has been designed to address the needs of gene therapy and vaccine innovators and CDMOs for robust and cost-effective upstream viral vectors manufacturing.
Univercells Technologies has introduced a new platform in the NevoLine biomanufacturing product family, the NevoLine Upstream platform.
This high-performance, low-footprint upstream manufacturing platform is suitable for multiple viral applications to support the booming gene therapy market and offers a cost-effective tool for rapid response to emerging infectious diseases.
The innovative design aims to revolutionize upstream processing by intensifying and chaining all unit operations from inoculation to midstream processing to deliver a concentrated, clarified bulk.
With the NevoLine Upstream platform, commercial-scale upstream production is possible in a 3-m² module, a 3-fold reduction in equipment footprint compared with conventional technologies.
The platform has been designed to address the needs of gene therapy and vaccine innovators and CDMOs for robust and cost-effective upstream viral vectors manufacturing.
It builds on the successful proof of concept with the first NevoLine biomanufacturing platform, which was specially designed for affordable production of a trivalent Sabin Inactivated Polio Vaccine (sIPV).
In application, the original NevoLine sIPV platform demonstrated how the chaining of unit operations could intensify processes for drastic footprint and cost reductions, with the ability to deliver more than 500,000 doses per batch below 0.30 EUR/dose, within a 10 m² equipment footprint.
The system accommodates all unit operations from inoculation to midstream processing and is suited for GMP, clinical and commercial manufacturing of vaccines, gene therapies and oncolytic viruses.
The automated platform offers a flexible solution for multiple viral applications by combining single-use assemblies in process-specific configurations. At the core of the platform is the scale-X nitro structured fixed-bed bioreactor, providing up to 600 m² of growth surface.
Mammalian cell culture and virus production can be combined with concentration and single or multi-step clarification for intensified and continuous processes that deliver high productivity with drastically reduced operational costs.
Related News
-
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News The 2024 Pharma Outsourcing Forecast: strategic partnerships across global landscapes
For the pharmaceutical industry, outsourcing drug development, manufacturing, and research operations to contract organisations is not just a passing trend – increasingly, the partnership between drug sponsor and drug vendor is one of vital impor... -
News Gerresheimer predicts weight-loss drug deals to account for 4% of yearly growth
Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class ... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Coronary drug-coated medical device receives US FDA approval
Boston Scientific announced the FDA approval of their medical device AGENT Drug-Coated Balloon (DCB) for the indication of coronary in-stent restenosis in coronary artery disease patients. -
News CPHI Online Webinar Series – Innovative Strategies for B2B Pharma Marketeers
On February 20, 2024, CPHI Online hosted a webinar on Innovative Strategies for B2B Pharma Marketeers. Featuring expert speakers from across the pharmaceutical value chain, this webinar delves into how B2B pharma marketeers can create better content to... -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance